{"organizations": [], "uuid": "8856d961fdabbeefa6cf4b6ef969d64f8aacdada", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-may-18-idUSL5N1SO5MC", "country": "US", "domain_rank": 408, "title": "Swiss stocks - Factors to watch on May 18", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.294, "site_type": "news", "published": "2018-05-18T12:59:00.000+03:00", "replies_count": 0, "uuid": "8856d961fdabbeefa6cf4b6ef969d64f8aacdada"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-may-18-idUSL5N1SO5MC", "ord_in_thread": 0, "title": "Swiss stocks - Factors to watch on May 18", "locations": [], "entities": {"persons": [], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "aimovig", "sentiment": "none"}, {"name": "ubs switzerland", "sentiment": "none"}, {"name": "india", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "richemont", "sentiment": "none"}, {"name": "economic times", "sentiment": "none"}, {"name": "amgen", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "richemont", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}, {"name": "cto", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, May 18 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Friday:\nRICHEMONT Swiss luxury goods group Richemont publishes results for its full year 2017/2018 to March. Markets expect solid constant currency growth, driven by strong jewellery sales and a recovery in watch demand. Focus on outlook, changes to digital strategy after surprise departure of CTO and size of inventory buybacks in Q4.\nDRUGS The U.S. Food and Drug Administration on Thursday listed a number of drugmakers, including Novartis, it said could be improperly blocking access to their medicines in order to delay generic competition.\nAmgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults. Amgen will market the drug, Aimovig, in partnership with Novartis.\nUBS Switzerland’s biggest bank is looking to double its headcount in India to 3,000 people by the end of the year, its CFO told India’s Economic Times, as it moves more of its back-office capabilities in-house.\nCOMPANY STATEMENTS * HBM Healthcare reported a 115.9 million franc profit for the 2017/18 financial year and proposed a 20 percent dividend hike to 7 francs.\nECONOMY (Reporting by Zurich newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-18T12:59:00.000+03:00", "crawled": "2018-05-18T08:08:55.008+03:00", "highlightTitle": ""}